" class="no-js "lang="en-US"> GenScript - Medtech Alert
Tuesday, May 28, 2024
GenScript | Pharmtech Focus

GenScript

About GenScript

GenScript

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform and the industrial synthesis product platform.

GenScript was founded in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript’s business operation spans over 100 countries and regions worldwide, with legal entities located in the U.S., Mainland China, Hong KongJapanSingaporeNetherlands and Ireland. GenScript has provided premium, convenient, and reliable products and services for over 100,000 customers.

GenScript has a number of intellectual property rights and technical secrets, including more than 100 patents and over 270 patent applications. As of December 31-st, 2020, GenScript’s products and services have been cited by 52,500 peer-reviewed journal articles worldwide.

Related Story

GenScript Expands Footprint in Singapore to Provide Premium Gene Synthesis Service

February 28 2023

GenScript Biotech Corporation, the world’s leading provider of life-science research tools and services, announced the […]

GenScript Partners with Allozymes to Accelerate Protein Discovery and Target Identification

December 7 2022

GenScript Biotech Corporation, the world’s leading provider of life-science research tools and services, is partnering […]

GenScript and Gladstone-UCSF Institute of Genomic Immunology Collaborate on Groundbreaking Non-Viral Cell Therapy Study

September 23 2022

GenScript USA Inc., the world’s leading life-science research tools and services provider, is collaborating with researchers at […]

GenScript and Avectas Team Up to Improve the Non-Viral Cell Therapy Manufacturing Process

September 20 2022

GenScript USA Inc., the world’s leading life-science research tools and services provider and Avectas, a cell engineering technology […]

Avacta Announces AffyXell Expands Its Strategic Partnership With GenScript ProBio

May 17 2022

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company developing innovative cancer therapies […]

GenScript Debuts Industry's Highest Throughput DNA Synthesis Platform for Commercial DNA Digital Data Storage

April 14 2022

GenScript USA Inc., the world’s leading life science research tools and services provider, announced today the debut […]